An observational study in Targeted Temperature Management, Cardiac Arrest and Resting Energy Expenditure, sponsored by Tang Ziren. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Tang Ziren · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.
Among the 37 studies in Heart Arrest with a site in China, this one is the 22nd largest by planned enrollment of the 28 observational ones that give a count, is one of 4 that started in 2024, is one of 28 observational ones, reaches primary completion later than 17 of the 21 other live ones, and was the 26th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:
Xiangya Hospital of Central South University · Sites in China
Ages 18–80
Central China Fuwai Hospital of Zhengzhou University · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–75
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18+
Renrong Gong · Sites in China
Ages 14–90 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 299 across the 9 interventional studies, 300 across the 28 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 37 have an industry lead sponsor. The 10 most frequent:
Tang Ziren is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Tang Ziren has 5 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Arrest with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07113769Central China Fuwai Hospital of Zhengzhou UniversityPlasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation | 2026-12-30 |
| NCT06353334Tang ZirenButylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial) | 2026-12-31 |
| NCT06974682Capital Medical UniversityEffect of Target Temperature Management on Intestinal Flora and Its Metabolites in Patients With Cardiac Arrest | 2027-06-01 |
| NCT06992843Xiangya Hospital of Central South UniversityNeuroprotection Bundles For Comatose Survivors Following Cardiac Arrest | 2027-08 |
| NCT06241261The University of Hong KongArresting Early Childhood Caries With a Silver Diamine Fluoride Gel | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Heart Arrest with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a single-center, prospective, observational study. According to the sample size formula, an estimated 40 cases should be collected, all of whom are from the emergency intensive care unit. After successful cardiopulmonary resuscitation, the enrolled patients will be transferred to the emergency intensive care unit for further standardized target temperature management (TTM). They will be divided into 33 ° C hypothermia group and 36 ° C hypothermia group according to the patient's core body temperature. The baseline data of the patients will be collected at the beginning. After admission to the hospital, they were fasted within 24 hours to reach the target temperature, and then 20kcal/kg/d parenteral nutrition will be given. At selected time points (T0: the initial time point before TTM; T1: the core temperature was reduced to 33 ° C or 36 ° C; T2-T4: 33 ° C or 36 ° C was maintained for 24h, 48h, 72h; T5: the end of rewarming; Tend: the last REE measurement before discharge or death) , various observation indicators will be collected, including resting energy expenditure (REE), glucose oxidation rate, fat oxidation rate, protein oxidation rate, and metabolism of three major nutrients Proportion. Neurological outcomes were followed up 28 days after onset according to the Cerebral Performance Categories (CPC) score.
Adult patients(age >18 years) who have been successfully resuscitated from cardiac arrest who meet the inclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: Target Temperature Management Treatment
Procedure: Target Temperature Management Treatment
Target Temperature Management Treatment
Resting Energy Expenditure
The primary outcome measure is the changes resting energy expenditure(REE) in the patients at various time points. patients at various time points.
Time frame: 7 days
Glucose oxidation rate
The primary outcome measure is the statistical differences in Glucose oxidation rate between the two groups of patients at various time points.
Time frame: 7 days
Fat oxidation rate
The primary outcome measure is the statistical differences in fat oxidation rate between the two groups of patients at various time points.
Time frame: 7 days
Protein oxidation rate
The primary outcome measure is the statistical differences in protein oxidation rate between the two groups of patients at various time points.
Time frame: 7 days
Metabolic supply proportion of glucose, fat, protein
The primary outcome measure is the statistical differences in metabolic supply proportion of glucose, fat, protein (measuring by indirect calorimetry) between the two groups of patients at various time points.
Time frame: 7 days
CPC score
CPC = Cerebral Performance Category Score.There are 5 levels of CPC score. CPC 1-2 means good prognosis of neurological function, CPC3-5 means bad prognosis of neurological function. The Secondary Outcome of the study is the statistical differences in the proportion of patients with good neurological outcome(CPC1-2) in the two groups at 28 days after CA.
Time frame: 28 days
Mortality rate
The Secondary Outcome of the study is the statistical differences in the mortality rate of two groups at 28 days after CA.
Time frame: 28 days
Plan to share: Yes
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Starting 6 months after publication
Access criteria: The identified survey data will be made available for research purposes by contacting the corresponding authors
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 54 months is above that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tang Ziren